All Submissions
A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Neoadjuvant Durvalumab in Combination With Gemcitabine+Cisplatin Followed by Adjuvant Durvalumab Alone in Muscle-Invasive Bladder Cancer: NIAGARA
Thomas Powles
0 views
0 downloads
Video
PDF
Abstract
0 Datasets
Powered by
Discover more research and events on
morressier.com
Imprint
Terms of Service
Privacy Policy
Accessibility